n Cardiovascular Journal of South Africa - Ezetimibe offers new opportunity to lower LDL-C to target levels : drug trends in cardiology
|Article Title||Ezetimibe offers new opportunity to lower LDL-C to target levels : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of South Africa|
|Publication Date||May 2005|
Extracted from text ... 174 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 3, May/June 2005 Ezetimibe (Ezetrol), a unique selective inhibitor of cholesterol absorption, is the first new cholesterol-lowering medication to be introduced, with FDA approval, in South Africa over the past 15 years. It offers the clinician an opportunity to lower LDL cholesterol by 65 to 80% in co-administration with a potent statin, such as atorvastatin or rosuvastatin. Prof. Derick Raal, head of the Lipid Clinic, University of the Witwatersrand and Johannesburg General Hospital, pointed out at the announcement of Ezetrol's availability on the South African market that ezetimibe is extremely well tolerated ..
Article metrics loading...